GlassScriptPhysician profile
Reem Jarbou
NPI 1578825857
$12,101.18
in general payments reported to CMS, 2019-2025
38 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $230 · 2021: $624 · 2022: $1,368 · 2023: $2,493 · 2024: $3,565 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,971.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,805.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,563.91 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,167.32 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $916.68 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $707.38 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $417.62 | 2022-2025 | Tremfya, Stelara |
| Genzyme Corporation | $373.81 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $372.30 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $305.60 | 2019-2025 | Vemlidy |
| Ardelyx, INC. | $296.72 | 2023-2025 | Ibsrela |
| Boston Scientific Corporation | $265.75 | 2022-2024 | Therasphere Y90 Glass Microspheres 10 Gbq, Exalt Model D |
| Aimmune Therapeutics, INC. | $222.94 | 2024-2025 | Zenpep |
| Celgene Corporation | $209.40 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $179.34 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $142.77 | 2020-2024 | Linzess |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $137.25 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $135.95 | 2019-2024 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $102.93 | 2024-2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $98.34 | 2022 | |
| Lilly USA, LLC | $69.87 | 2022-2025 | Omvoh |
| Qol Medical, LLC | $68.47 | 2019-2025 | Sucraid |
| Redhill Biopharma INC. | $67.20 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Daiichi Sankyo INC. | $49.31 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $48.00 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $44.52 | 2021-2025 | Verquvo |
| Abbott Laboratories | $40.48 | 2022-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $34.05 | 2024 | Farxiga |
| Concordia Pharmaceuticals INC. | $33.17 | 2019 | |
| Celltrion USA INC. | $32.45 | 2025 | Vegzelma |
| Pharming Healthcare, INC. | $27.72 | 2025 | Ruconest |
| Organon LLC | $27.45 | 2023 | Renflexis |
| Shionogi INC | $25.22 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.05 | 2025 | Givlaari |
| Evoke Pharma, INC. | $22.50 | 2021 | |
| Novo Nordisk INC | $21.48 | 2025 | Wegovy |
| Capsovision, INC. | $15.91 | 2025 | Capsocam Plus |
| Otsuka America Pharmaceutical, INC. | $14.91 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $12.81 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Jarbou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.